Bio-Rad Laboratories BIO Clinical Diagnostics — Goodwill, Foreign Currency Translation, Gain (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — goodwill, foreign currency translation, gain (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Bio-Rad Laboratories's clinical diagnostics — goodwill, foreign currency translation, gain (loss)?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — goodwill, foreign currency translation, gain (loss) of $0 in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — goodwill, foreign currency translation, gain (loss) changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — goodwill, foreign currency translation, gain (loss) decreased by 100.0% year-over-year, from $4.1M to $0.
- What does clinical diagnostics — goodwill, foreign currency translation, gain (loss) mean?
- The impact of fluctuations in foreign exchange rates on the carrying value of goodwill denominated in currencies other than the reporting currency for the Clinical Diagnostics segment. This reflects non-cash adjustments due to global operations.